PPARG and melanoma: The PPARγ specific agonists 15-deoxy-Δ12,14 prostaglandin J2 (15d-PGJ2), troglitazone, and rosiglitazone inhibited cell proliferation in four melanoma cell lines dose-dependently, whereas a specific agonist of peroxisome proliferator-activated receptor alpha (WY-14643) did not exert this effect [9].